Sales of finished products Veropharm on the basis of 1 half of 2009 decreased by 14% compared to the same period of 2008 and amounted to $ 74.3 million (in ruble terms, sales increased by 19% and amounted to 2 457.8 million).

Sales prescription drugs accounted for $ 51.5 million, a 9% decrease compared to 1 half of 2008 (in ruble terms, sales amounted to 1 701.6 million, which is 27% higher compared to 1 half of 2008) . The percentage of prescription drugs in the total sales of finished products grew to 69%.

Sales of traditional products were $ 1.9 million, which is 70% less compared to 1 half of 2008 (in ruble terms, sales amounted to 62.7 million, which is 58% less compared to 1 half of 2008). The share of traditional products in total sales of finished products had fallen to 3%.

plasters Sales amounted to $ 13.0 million, which is 22% less than in the first six months of 2008 (in ruble terms, sales totaled 430.3 million, an 8% increase compared to the first half of 2008). The proportion of patches in the total sales of finished products was 18%.

OTC drugs sales amounted to $ 7.9 million, up 13% compared to 1 half of 2008 (in ruble terms, sales totaled 263.2 million, which is 56% higher compared to 1 half of 2008). The proportion of OTC drugs in the total sales of finished products was 10%.

Sales Veropharm under the state program for an additional drug (proposals) amounted to $ 2.2 million, which corresponds to 2.9% from sales of finished products. At the end of 1 half of 2008 sales through the proposals amounted to $ 3.3 million or 3.8% of sales of finished products.

sales in the territory of the Russian Federation have provided 98% of sales of finished products in 1 half of 2009, the report says Veropharm.

The total sales of the five best-selling prescription drugs on the basis of 1 semester of 2009 amounted to $ 20.8 million (in ruble terms - 686.6 million), which corresponds to 40% of sales in the area of drug and 28% of sales finished products.

The total sales of the five best-selling traditional drugs on the basis of 1 semester of 2009 amounted to $ 1.3 million (in ruble terms - 44.5 million), which corresponds to 71% of sales in the traditional segment, and 2% from sales of finished products of JSC Veropharm.

At the end of 1 half of 2009, debt Veropharm amounted to $ 25.9 million, which does not exceed 25% of the value of net assets of the company.
The objectives of futures on the RTS index, with its growth - 116 of 000 items
For gold futures on the alleged purpose of sales is located in the region of $ 900-920
Polyus Gold has reduced the production of gold in the I half of 2009 by 14% to 14.9 tonnes
RZD will hold two auctions on sale of 25% of its daughters
In stock bid for Asian dominance is the color red
Kommersant: Public sector is well preserved
U.S. blamed speculators for inflated oil prices
Tymoshenko hopes that the third tranche of the IMF loan will be in Ukraine until the end of the week
Kommersant: Deutsche Bank is not convinced the market for profit